EA200300937A1 - Оральная фармацевтическая композиция цефподоксима проксетила - Google Patents

Оральная фармацевтическая композиция цефподоксима проксетила

Info

Publication number
EA200300937A1
EA200300937A1 EA200300937A EA200300937A EA200300937A1 EA 200300937 A1 EA200300937 A1 EA 200300937A1 EA 200300937 A EA200300937 A EA 200300937A EA 200300937 A EA200300937 A EA 200300937A EA 200300937 A1 EA200300937 A1 EA 200300937A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
cefpodoxima
proxetyl
oral pharmaceutical
oral
Prior art date
Application number
EA200300937A
Other languages
English (en)
Other versions
EA006974B1 (ru
Inventor
Мукта Малхотра
Раджив Шанкар Матхур
Раджив Малик
Original Assignee
Ранбакси Лабораторис Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11097036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200300937(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ранбакси Лабораторис Лимитед filed Critical Ранбакси Лабораторис Лимитед
Publication of EA200300937A1 publication Critical patent/EA200300937A1/ru
Publication of EA006974B1 publication Critical patent/EA006974B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к стабильной фармацевтической композиции цефподоксима проксетила для орального применения.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200300937A 2001-02-27 2002-02-27 Оральная фармацевтическая композиция цефподоксима проксетила EA006974B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN190DE2001 2001-02-27
PCT/IB2002/000602 WO2002067943A1 (en) 2001-02-27 2002-02-27 Oral pharmaceutical composition of cefpodoxime proxetil

Publications (2)

Publication Number Publication Date
EA200300937A1 true EA200300937A1 (ru) 2004-04-29
EA006974B1 EA006974B1 (ru) 2006-06-30

Family

ID=11097036

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300937A EA006974B1 (ru) 2001-02-27 2002-02-27 Оральная фармацевтическая композиция цефподоксима проксетила

Country Status (14)

Country Link
EP (1) EP1365764B1 (ru)
JP (1) JP2004522782A (ru)
KR (1) KR20030087009A (ru)
CN (1) CN1505515A (ru)
AT (1) ATE303149T1 (ru)
AU (1) AU2002237462B2 (ru)
BR (1) BR0207640A (ru)
DE (1) DE60205870T2 (ru)
EA (1) EA006974B1 (ru)
ES (1) ES2248521T3 (ru)
MX (1) MXPA03007678A (ru)
NZ (1) NZ527867A (ru)
OA (1) OA12687A (ru)
WO (1) WO2002067943A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6766376B2 (en) 2000-09-12 2004-07-20 Sn Acquisition, L.L.C Streaming media buffering system
DE60324944D1 (de) * 2002-08-16 2009-01-08 Orchid Chemicals & Pharm Ltd Pharmazeutische zusammensetzung mit verzögerte freisetzung enthaltend einen cephalosporin-antibiotikum
WO2004016250A1 (en) * 2002-08-19 2004-02-26 Orchid Health Care Sustained release pharmaceutical composition of a cephalosporin antibiotic
WO2004105728A2 (en) * 2003-05-27 2004-12-09 Ranbaxy Laboratories Limited Solid dispersions of cefpodoxime proxetil and processes for their preparation
WO2007017895A2 (en) * 2005-05-05 2007-02-15 Lupin Limited Stabilized oral pharmaceutical compositions of cephalosporins
WO2008010784A1 (en) * 2005-05-16 2008-01-24 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising a cephalosporin
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins
WO2008057058A1 (en) * 2006-11-10 2008-05-15 Nobel Ilac Sanayii Ve Ticaret As Oral pharmaceutical compositions
CN101278914B (zh) * 2008-01-02 2010-06-02 海南三叶美好制药有限公司 头孢泊肟酯干混悬剂组合物及其制备方法
TR201001417A1 (tr) * 2010-02-25 2011-09-21 Sanovel İlaç San. Ve Ti̇c. A. Ş. Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
TR201002878A2 (tr) 2010-04-13 2011-10-21 Bi̇lgi̇ç Mahmut Sefpodoksim proksetil içeren farmasötik bileşimler.
EP2575812A2 (en) * 2010-06-03 2013-04-10 Mahmut Bilgic Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid
TR201007106A1 (tr) * 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Sefpodoksim proksetil formülasyonları.
TR201007107A1 (tr) * 2010-08-25 2012-03-21 Bi̇lgi̇ç Mahmut Tat düzenleyici ajan içeren sefpodoksim proksetil formülasyonları.
TR201009168A2 (tr) * 2010-11-05 2012-05-21 Bi̇lgi̇ç Mahmut Suda dağılan sefpodoksim proksetil formülasyonları.
PT2647648T (pt) * 2010-12-03 2017-10-02 Nippon Soda Co Forma de dosagem sólida que contém uma hidroxialquil celulose de baixa viscosidade
JP6062422B2 (ja) * 2012-03-29 2017-01-18 杏林製薬株式会社 カプセル製剤
TR201904884T4 (tr) 2012-07-27 2019-05-21 Redhill Biopharma Ltd Koloni̇k boşaltmada kullanima yöneli̇k formülasyonlar ve formülasyonlarin üreti̇m yöntemleri̇
CN103142506B (zh) * 2013-04-03 2015-02-25 天津医药集团津康制药有限公司 一种头孢泊肟酯颗粒剂及其制备方法
EP2990038B1 (en) 2013-04-25 2019-11-20 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
EP2990039A4 (en) * 2013-04-25 2017-02-22 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
KR101509168B1 (ko) * 2013-06-10 2015-04-06 한국화학연구원 세팔로스포린 항생제의 서방형 제제 및 이를 포함하는 서방형 약제학적 조성물
CN103301075B (zh) * 2013-06-28 2015-11-18 山东罗欣药业集团股份有限公司 一种头孢克肟组合物混悬颗粒剂及其制备方法
JP6292788B2 (ja) * 2013-07-30 2018-03-14 ライオン株式会社 錠剤及び錠剤の製造方法
JP2016204260A (ja) * 2013-10-04 2016-12-08 日本曹達株式会社 錠剤の製造方法
EP3210607A4 (en) 2014-10-23 2018-06-06 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
CN104771368B (zh) * 2015-04-08 2017-12-22 石家庄四药有限公司 头孢泊肟酯速释制剂及其制备方法
CN113456599A (zh) * 2020-03-30 2021-10-01 洛阳惠中兽药有限公司 一种头孢泊肟酯片的制备方法及其制备的头孢泊肟酯片
CN113952313A (zh) * 2021-08-26 2022-01-21 宁夏医科大学 一种头孢呋辛酯胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486425A (en) * 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
US5929086A (en) * 1996-05-10 1999-07-27 Pharmacia & Upjohn Company Topical administration of antimicrobial agents for the treatment of systemic bacterial diseases
AT500063A1 (de) * 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
EP2263654B1 (en) * 2000-06-21 2012-10-10 Cubist Pharmaceuticals, Inc. Compositions for improving the oral absorption of antimicrobial agents

Also Published As

Publication number Publication date
EP1365764A4 (en) 2004-08-11
DE60205870T2 (de) 2006-06-29
AU2002237462B2 (en) 2006-05-18
DE60205870D1 (de) 2005-10-06
BR0207640A (pt) 2004-07-27
EA006974B1 (ru) 2006-06-30
MXPA03007678A (es) 2004-03-16
KR20030087009A (ko) 2003-11-12
EP1365764B1 (en) 2005-08-31
JP2004522782A (ja) 2004-07-29
EP1365764A1 (en) 2003-12-03
WO2002067943A1 (en) 2002-09-06
ATE303149T1 (de) 2005-09-15
CN1505515A (zh) 2004-06-16
ES2248521T3 (es) 2006-03-16
NZ527867A (en) 2004-12-24
OA12687A (en) 2006-06-21

Similar Documents

Publication Publication Date Title
EA200300937A1 (ru) Оральная фармацевтическая композиция цефподоксима проксетила
CO5590918A2 (es) Formulaciones
CY1105387T1 (el) Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου
DE60225040D1 (de) Montelukast-granulatformulierung
SE0101675D0 (sv) Novel composition
HUP0202400A2 (hu) Prosztaglandinszármazékot tartalmazó készítmény külső elválasztási rendellenességek kezelésére
SE0302760D0 (sv) New compounds
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
CY1105039T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ ΒΕΝΖΟ[b]ΑΖΕΠΙΝ-2-ΟΝΗΣ
SE9901077D0 (sv) Novel use
BR0311189A (pt) Composições farmacêuticas contendo polimorfo a de flibanserin
CY1105275T1 (el) Ενωσεις υποκατεστημενης γ-λακτονης ως ανταγωνισται - νμda
SE9801494D0 (sv) Novel use
MXPA06000636A (es) Formulaciones semi-solidas para la administracion oral de taxoides.
TNSN06013A1 (en) Semi-solid systems containing azetidine derivatives
DK1206452T3 (da) Fremgangsmåde til fremstilling af benzoperhydro-isoindolforbindelser
ATE328595T1 (de) Carvedilolpolymorph
MXPA03009639A (es) Uso de derivados de piridoindolona para preparar medicinas anticancer.
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης
SE0101220D0 (sv) New use
DK1399143T3 (da) Anvendelsen af Acetyl L-carnitin til fremstilling af et lægemiddel til behandling af anhedoni
SE9901340D0 (sv) Novel process
DE60102704D1 (de) Trioxepan verbindungen

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU